RSC medicinal chemistry最新文献_第2页

Minimalistic bis-triarylpyridinium cations: effective antimicrobials against bacterial and fungal pathogens. 最小化双三芳基吡啶阳离子：针对细菌和真菌病原体的有效抗菌剂。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-18 DOI: 10.1039/d4md00902a

Ana M López-Fernández, Jean C Neto, Rosa de Llanos, Juan F Miravet, Francisco Galindo

{"title":"Minimalistic bis-triarylpyridinium cations: effective antimicrobials against bacterial and fungal pathogens.","authors":"Ana M López-Fernández, Jean C Neto, Rosa de Llanos, Juan F Miravet, Francisco Galindo","doi":"10.1039/d4md00902a","DOIUrl":"10.1039/d4md00902a","url":null,"abstract":"A series of twelve compounds from the family of 2,4,6-triarylpyridinium cations have been synthesized, chemically characterized (1H, 13C NMR, HRMS), and microbiologically evaluated (MIC determination against S. aureus, E. faecalis, E. coli, P. aeruginosa, and C. albicans). These compounds are quaternary ammonium cations (QACs), classified as either mono-QACs or bis-QACs. The mono-QACs are further divided into those with short (three-carbon) and long (twelve-carbon) pendant chains. An additional structural variable is the number of bromine atoms attached to the aromatic rings, ranging from zero to three. The major findings of this study are: (a) bis-QACs exhibit notably higher antimicrobial activity than mono-QACs; (b) an increased number of bromine atoms on the structure appears to diminish antimicrobial properties and (c) one of the compounds (1a) shows particularly promising properties as a broad spectrum antimicrobial, given its low MICs across all five pathogenic microorganisms studied. Preliminary assays with C. albicans show that 1a has a strong mitochondrial activity, causing a remarkable mitochondrial membrane depolarization in this organelle. Taken together, this study positions triarylpyridinium cations-previously unexplored as antimicrobials-as promising candidates for future drug development, especially in light of the growing concern over drug-resistant microorganisms.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Structure-guided design of a truncated heterobivalent chemical probe degrader of IRE1α. 截断型IRE1α异二价化学探针降解物的结构导向设计。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-18 DOI: 10.1039/d5md00028a

Breanna L Zerfas, Yingpeng Liu, Jianwei Che, Katherine A Donovan, John M Hatcher, Fidel Huerta, Rebecca J Metivier, Radosław P Nowak, Leah Ragosta, Tiffany Tsang, Eric S Fischer, Lyn H Jones

{"title":"Structure-guided design of a truncated heterobivalent chemical probe degrader of IRE1α.","authors":"Breanna L Zerfas, Yingpeng Liu, Jianwei Che, Katherine A Donovan, John M Hatcher, Fidel Huerta, Rebecca J Metivier, Radosław P Nowak, Leah Ragosta, Tiffany Tsang, Eric S Fischer, Lyn H Jones","doi":"10.1039/d5md00028a","DOIUrl":"10.1039/d5md00028a","url":null,"abstract":"IRE1α is an ER protein involved in the unfolded protein response (UPR) and dysregulation of the ER stress pathway has been implicated in several diseases. Inhibitors of the cytoplasmic endonuclease or kinase domains of the enzyme have limited utility and targeted degradation would address additional scaffolding functions of the protein. Here, we describe the design and development of IRE1α proteolysis targeting chimeras (PROTACs) based on a lysine-reactive salicylaldehyde RNase inhibitor, and present the structure-activity relationships (SARs) that delivered the first highly selective degraders of a native ER-membrane associated protein. Medicinal chemistry optimization exploited ternary complex computational modelling to inform design, HiBiT-SpyTag IRE1α degradation and NanoBRET cereblon occupancy cell-based assays to generate SARs, and mass spectrometry-based proteomics to assess broad selectivity in an unbiased manner. Merging IRE1α and CRBN ligand chemotypes provided the truncated chimera CPD-2828 with physicochemical properties more akin to an oral molecular glue degrader than a traditional PROTAC.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Light-activatable photochemically targeting chimeras (PHOTACs) enable the optical control of targeted protein degradation of HDAC6. 光激活的光化学靶向嵌合体（PHOTACs）能够光学控制HDAC6的靶向蛋白降解。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-13 DOI: 10.1039/d4md00972j

Silas L Wurnig, Maria Hanl, Thomas M Geiger, Shiyang Zhai, Ina Dressel, Dominika E Pieńkowska, Radosław P Nowak, Finn K Hansen

{"title":"Light-activatable photochemically targeting chimeras (PHOTACs) enable the optical control of targeted protein degradation of HDAC6.","authors":"Silas L Wurnig, Maria Hanl, Thomas M Geiger, Shiyang Zhai, Ina Dressel, Dominika E Pieńkowska, Radosław P Nowak, Finn K Hansen","doi":"10.1039/d4md00972j","DOIUrl":"10.1039/d4md00972j","url":null,"abstract":"Proteolysis targeting chimeras (PROTACs) are heterobifunctional modalities that induce protein degradation via a catalytic mode of action. Photochemically targeting chimeras (PHOTACs) are a subset of PROTACs designed for light-activated protein degradation, thereby offering precise spatiotemporal control. In this study, we report the design, solid-phase synthesis, and characterization of the first PHOTACs targeting histone deacetylase 6 (HDAC6). We achieved this by incorporating an azobenzene photoswitch into our previously developed HDAC6-selective PROTAC A6. Among the synthesized compounds, PHOTAC 12 demonstrated no HDAC6 degradation in the absence of light but showed significant degradation upon activation to its cis-state with 390 nm light irradiation. Notably, we find that PHOTAC 12 in the cis-state shows significantly improved ternary complex formation compared to the trans-state correlating with its degradation efficacy. Overall, PHOTAC 12 is a promising lead compound for the development of light-activatable HDAC6 degraders.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development, biological evaluation, and molecular modelling of novel isocytosine and guanidine derivatives as BACE1 inhibitors using a fragment growing strategy. 基于片段生长策略的新型异胞嘧啶和胍衍生物作为BACE1抑制剂的开发、生物学评价和分子建模。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-13 DOI: 10.1039/d4md00698d

Asmaa M Atta, Nouran Rihan, Ahmad M Abdelwaly, Mohamed S Nafie, Mohamed S Elgawish, Samia M Moustafa, Mohamed A Helal, Khaled M Darwish

{"title":"Development, biological evaluation, and molecular modelling of novel isocytosine and guanidine derivatives as BACE1 inhibitors using a fragment growing strategy.","authors":"Asmaa M Atta, Nouran Rihan, Ahmad M Abdelwaly, Mohamed S Nafie, Mohamed S Elgawish, Samia M Moustafa, Mohamed A Helal, Khaled M Darwish","doi":"10.1039/d4md00698d","DOIUrl":"https://doi.org/10.1039/d4md00698d","url":null,"abstract":"Alzheimer's disease (AD) is a neurodegenerative condition characterized by significant synaptic loss and neuronal death in brain regions critical for cognitive functions. The disease is characterized by the formation of amyloid plaques, which are extracellular constructs consisting mainly of aggregated Aβ42. The latter is a peptide formed by the proteolytic cleavage of β-amyloid precursor protein (APP) by two enzymes, β- and γ-secretase. Therefore, inhibition of the aspartic protease β-secretase (BACE1) is considered a promising therapeutic approach for the treatment and prevention of Alzheimer's disease. Unfortunately, a limited number of β-secretase inhibitors have reached human trials and eventually failed due to inconclusive therapeutic and/or safety profiles. In this study, we developed drug-like molecules with a β-secretase inhibitory activity using a fragment growing strategy on isocytosine and acyl guanidine warheads. Our approach is based on optimizing the hydrophobic part of the molecules to obtain a conformationally restrained scaffold complementary to the hydrophobic pockets within the enzyme active site. We developed 32 compounds with promising in vitro inhibitory activity against BACE1 down to sub-micromolar IC50. Docking simulation studies were performed to understand the mode of binding of the prepared compounds. We demonstrated that compounds with superior activities, such as 16b and 16g, are able to provide the best balance between the steric shape and position of the polar substituent for achieving preferential anchoring into the S1, S3, S1', and S2' sub-pockets. Further, in vivo characterization of selected drug-like candidates of the benzimidazole series AMK-IV, namely 16a and 16k, demonstrated their ability to reduce oxidation stress and their safety within brain and liver tissues.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring medium and long arm extensions of 1,2,4-triazole derivatives as Candida albicans 14α-demethylase (CYP51) inhibitors. 探索1,2,4-三唑衍生物作为白色念珠菌14α-去甲基化酶（CYP51）抑制剂的中、长臂延伸

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-12 DOI: 10.1039/d4md00863d

Marwa Alsulaimany, Faizah A Binjubair, Esra Tatar, Diane E Kelly, Steven L Kelly, Andrew G Warrilow, Mikhail V Keniya, Brian C Monk, Josie E Parker, Claire Simons

引用次数: 0

Conceptual expansion of photomedicine for spatiotemporal treatment methods. 时空治疗方法的光电医学概念扩展。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-11 DOI: 10.1039/d4md01005a

P K Hashim, Ashwin T Shaji, Ammathnadu S Amrutha, Shifa Ahmad

引用次数: 0

Design, synthesis, and SAR of antiproliferative activity of trioxatriangulene derivatives. 三氧杂三庚烯衍生物抗增殖活性的设计、合成和 SAR。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-07 DOI: 10.1039/d4md00867g

Mohinder Maheshbhai Naiya, Ivy A Guan, Matthew Sullivan, Chatchakorn Eurtivong, Euphemia Leung, Lisa I Pilkington, David Barker

{"title":"Design, synthesis, and SAR of antiproliferative activity of trioxatriangulene derivatives.","authors":"Mohinder Maheshbhai Naiya, Ivy A Guan, Matthew Sullivan, Chatchakorn Eurtivong, Euphemia Leung, Lisa I Pilkington, David Barker","doi":"10.1039/d4md00867g","DOIUrl":"10.1039/d4md00867g","url":null,"abstract":"Trioxatriangulene (TOTA+) and its derivatives, which are primarily used as dyes in biological systems, have received considerable attention owing to their photophysical and electronic properties. Notably, their DNA-intercalating properties have been well established. Previous studies have identified TOTA+ derivatives, particularly ADOTA+ (R = -C3H7) and DAOTA+ (R = R' = -C3H7), as potent antiproliferative agents in triple-negative breast cancer (MDA-MB-231) and colorectal cancer (HCT-116) cell lines. However, the potential to enhance antiproliferative activity through different side chains prompted further investigation. In addition, partially cyclized tetramethoxyphenyl acridinium ion (TMPA+8) and dimethoxy quinacridinium ion (DMQA+9) intermediates were assessed to elucidate the structure-activity relationship (SAR) of the triangulenium core for antiproliferative activity. In this study, 83 molecules with various side chains were synthesized, including planar, partially planar, and non-planar derivatives. Evaluation of their antiproliferative activity in MDA-MB-231 and HCT-116 cell lines revealed that compound 6l (R = -C4H9, R' = -C2H4N(Me)2) was the most potent inhibitor, with IC50 values of 18 ± 3 nM and 32 ± 14 nM, respectively. A new one-pot method was developed to synthesize symmetrically and asymmetrically substituted DAOTA+ molecules, enabling the introduction of acid-labile functional groups, such as alcohols, ethers, and alkylamines, in moderate to good yields.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Silicon incorporated tacrine: design, synthesis, and evaluation of biological and pharmacokinetic parameters. 硅合成塔克林：生物和药代动力学参数的设计、合成和评价。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-07 DOI: 10.1039/d5md00019j

Akshay S Kulkarni, Sreenivasa Rao Ramana, Vijay K Nuthakki, Shipra Bhatt, Ashiya Jamwal, Laxman D Nandawadekar, Anshika Jotshi, Ajay Kumar, Utpal Nandi, Sandip B Bharate, D Srinivasa Reddy

{"title":"Silicon incorporated tacrine: design, synthesis, and evaluation of biological and pharmacokinetic parameters.","authors":"Akshay S Kulkarni, Sreenivasa Rao Ramana, Vijay K Nuthakki, Shipra Bhatt, Ashiya Jamwal, Laxman D Nandawadekar, Anshika Jotshi, Ajay Kumar, Utpal Nandi, Sandip B Bharate, D Srinivasa Reddy","doi":"10.1039/d5md00019j","DOIUrl":"10.1039/d5md00019j","url":null,"abstract":"Tacrine, an orally bioavailable cholinesterase inhibitor, was previously used to treat Alzheimer's disease but was withdrawn due to hepatotoxicity. The unique structural features of tacrine have once again captured the interest of medicinal chemists. However, the blood-brain barrier (BBB) permeability hampered the development of the majority of its new analogs. Herein, we employed a silicon switch approach for improving the BBB permeability of CNS drugs with tacrine as a tool compound. The replacement of C2 methylene of tacrine with dimethyl silicon yielded 'sila-tacrine' that inhibits acetylcholinesterase as well as butyrylcholinesterase with IC50 values of 3.18 and 6.09 μM, respectively. Sila-tacrine competitively inhibits acetylcholinesterase while it is a non-competitive inhibitor of butyrylcholinesterase. The molecular docking results corroborated with the in vitro cholinesterase inhibition activity of tacrine vs. sila-tacrine. Sila-tacrine demonstrated metabolic stability in HLM and MLM and exhibited superior plasma exposure in an oral pharmacokinetic study in Swiss albino mice. However, tissue distribution studies revealed lower-than-expected brain levels due to efflux pump-mediated transport. This study offers a proof-of-concept for the silicon switch approach in improving the BBB permeability of CNS-active compounds.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design, synthesis and evaluation of acetylcholine-antitumor lipid hybrids led to identification of a potential anticancer agent disrupting the CDK4/6-Rb pathway in lung cancer. 乙酰胆碱-抗肿瘤脂质杂合体的设计、合成和评价导致了一种潜在的抗癌药物在肺癌中破坏CDK4/6-Rb通路。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-07 DOI: 10.1039/d4md01007h

Ahmed H E Hassan, Eun Seo Bae, Youngdo Jeong, Chae Won Ock, Selwan M El-Sayed, Minji Kim, Mohamed F Radwan, Tarek S Ibrahim, Jun-Young Cho, Boyoung Y Park, Jaehoon Sim, Sang Kook Lee, Yong Sup Lee

{"title":"Design, synthesis and evaluation of acetylcholine-antitumor lipid hybrids led to identification of a potential anticancer agent disrupting the CDK4/6-Rb pathway in lung cancer.","authors":"Ahmed H E Hassan, Eun Seo Bae, Youngdo Jeong, Chae Won Ock, Selwan M El-Sayed, Minji Kim, Mohamed F Radwan, Tarek S Ibrahim, Jun-Young Cho, Boyoung Y Park, Jaehoon Sim, Sang Kook Lee, Yong Sup Lee","doi":"10.1039/d4md01007h","DOIUrl":"10.1039/d4md01007h","url":null,"abstract":"Hybridization of acetylcholine with antitumor lipids (ATLs) was explored to achieve novel potential anticancer agents. The combination with a 2-stearoxyphenyl moiety substantially enhanced the anticancer activity of the acetylcholine hybrids. Compounds 6, 8, 9 and 10 exhibited pronounced anticancer activities higher than edelfosine and stPEPC and NSC43067. Compounds 6, 8, 9 and 10 also showed broad-spectrum anticancer activity against diverse cancer cells including lung, ovarian, renal, prostate, leukaemia, colon, CNS, melanoma, and breast cancer cells. Compounds 6 and 8 were potent compounds eliciting single digit low micromolar GI50 values. Compound 6 was the most potent against non-small cell lung cancer, ovarian cancer, renal cancer, and prostate cancer. Meanwhile, compound 8 was the most potent against leukaemia, colon cancer, CNS cancer, melanoma, and breast cancer. Exploration of the mechanism of action of compound 6 in A549 non-small cell lung cancer cells showed that it triggers cell cycle arrest in the G0/G1 phase via disruption of the CDK4/6-Rb pathway and induces apoptosis via the activation of caspases, upregulation of BAX and cleavage of PARP. Overall, the results present acetylcholine-ATL hybrids 6 and 8 as potential anticancer agents for possible further development.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nitroreductase-activatable photosensitizers for selective antimicrobial photodynamic therapy. 用于选择性抗菌光动力治疗的硝基还原酶活化光敏剂。

IF 4.1 4区医学

RSC medicinal chemistry Pub Date : 2025-03-06 DOI: 10.1039/d4md00890a

Matthew T Tung, Tianyi Ma, Ivonne Rebeca Lopez-Miranda, Joshua N Milstein, Andrew A Beharry

{"title":"Nitroreductase-activatable photosensitizers for selective antimicrobial photodynamic therapy.","authors":"Matthew T Tung, Tianyi Ma, Ivonne Rebeca Lopez-Miranda, Joshua N Milstein, Andrew A Beharry","doi":"10.1039/d4md00890a","DOIUrl":"10.1039/d4md00890a","url":null,"abstract":"Antimicrobial photodynamic therapy (aPDT) utilizes light, oxygen and a photosensitizer (PS) to enact cell death via the production of reactive oxygen species (ROS). This mechanism of cell death, via oxidative stress, has allowed aPDT to be effective against antibiotic-resistant bacterial strains, with the development of resistance being minimal as no specific pathway is targeted. While promising, as ambient light can activate PSs, damage to mammalian tissues can occur, leading to drug-induced photosensitivity. To mitigate this, we developed a nitroreductase-activatable PS containing a quenching group that inhibits fluorescence and ROS. Upon reaction with nitroreductase, the quenching group can be liberated, restoring fluorescence and ROS production. As nitroreductase is not present in healthy mammalian tissues but expressed in many bacteria, photosensitivity of mammalian cells can be reduced. Herein, the synthesis and photophysical characterization of the nitroreductase-activatable PS, DB2, is described. DB2 was quenched compared to the free PS, DB1, and activation both in vitro by purified nitroreductase and in the gram-positive bacterial strain, Bacillus subtilis, was confirmed by fluorescence recovery. Cell viability studies in B. subtilis showed low dark toxicity and an IC50 of 0.16 μM under 10-minute irradiation (530 nm, 42 mW cm-2). Minimal toxicity was observed under the same conditions in mammalian cell cultures demonstrating the potential of DB2 to mitigate photosensitivity and provide a promising approach for aPDT.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0